Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 2
1979 2
1980 5
1981 2
1982 1
1983 2
1984 5
1985 3
1986 3
1987 2
1988 9
1989 16
1990 26
1991 21
1992 29
1993 25
1994 37
1995 36
1996 37
1997 32
1998 38
1999 32
2000 47
2001 42
2002 43
2003 54
2004 36
2005 39
2006 37
2007 46
2008 52
2009 68
2010 82
2011 92
2012 76
2013 84
2014 98
2015 100
2016 119
2017 143
2018 145
2019 148
2020 141
2021 191
2022 159
2023 136
2024 57

Text availability

Article attribute

Article type

Publication date

Search Results

2,280 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "B-cell childhood acute lymphoblastic leukemia"
Page 1
Update on Lymphoblastic Leukemia/Lymphoma.
Luca DC. Luca DC. Clin Lab Med. 2021 Sep;41(3):405-416. doi: 10.1016/j.cll.2021.04.003. Clin Lab Med. 2021. PMID: 34304772 Review.
Lymphoblastic leukemias/lymphomas are predominantly diseases of childhood, where they represent almost all acute leukemias; however, they are also encountered with significant frequency in the adult population. These neoplastic processes can be of B- …
Lymphoblastic leukemias/lymphomas are predominantly diseases of childhood, where they represent almost all acute leukem …
Genetic Biomarkers and Their Clinical Implications in B-Cell Acute Lymphoblastic Leukemia in Children.
Lejman M, Chałupnik A, Chilimoniuk Z, Dobosz M. Lejman M, et al. Int J Mol Sci. 2022 Mar 2;23(5):2755. doi: 10.3390/ijms23052755. Int J Mol Sci. 2022. PMID: 35269896 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies characterized by abnormal proliferation of immature lymphoid cells. It is the most commonly diagnosed childhood cancer with an almost 80% cure rate. Despite favorab …
Acute lymphoblastic leukemia (ALL) is a heterogeneous group of hematologic malignancies characterized by abnormal proli …
Single-cell analysis identifies dynamic gene expression networks that govern B cell development and transformation.
Lee RD, Munro SA, Knutson TP, LaRue RS, Heltemes-Harris LM, Farrar MA. Lee RD, et al. Nat Commun. 2021 Nov 25;12(1):6843. doi: 10.1038/s41467-021-27232-5. Nat Commun. 2021. PMID: 34824268 Free PMC article.
We use single-cell transcriptomics/proteomics to identify differentially expressed gene networks across B cell development and correlate these networks with subtypes of B cell leukemia. ...Our findings demonstrate the underlying heterogen …
We use single-cell transcriptomics/proteomics to identify differentially expressed gene networks across B cell developm …
Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C, Faul C, Brüggemann M, Taylor K, Mergen N, Reichle A, Horst HA, Havelange V, Topp MS, Bargou RC. Gökbuget N, et al. Leuk Lymphoma. 2020 Nov;61(11):2665-2673. doi: 10.1080/10428194.2020.1780583. Epub 2020 Jul 3. Leuk Lymphoma. 2020. PMID: 32619115
Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). ...
Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphob …
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001.
Tran TH, Langlois S, Meloche C, Caron M, Saint-Onge P, Rouette A, Bataille AR, Jimenez-Cortes C, Sontag T, Bittencourt H, Laverdière C, Lavallée VP, Leclerc JM, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Michon B, Santiago R, Stevenson KE, Welch JJG, Schroeder KM, Koch V, Cellot S, Silverman LB, Sinnett D. Tran TH, et al. Blood Adv. 2022 Feb 22;6(4):1329-1341. doi: 10.1182/bloodadvances.2021005634. Blood Adv. 2022. PMID: 34933343 Free PMC article. Clinical Trial.
The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent, prognostic genetic alterations, many of which are cryptic by conventional cytogenetics. ...An additional 56 gene fusions were identified by RNA …
The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by recurrent, prognos …
Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response.
Lee SHR, Yang W, Gocho Y, John A, Rowland L, Smart B, Williams H, Maxwell D, Hunt J, Yang W, Crews KR, Roberts KG, Jeha S, Cheng C, Karol SE, Relling MV, Rosner GL, Inaba H, Mullighan CG, Pui CH, Evans WE, Yang JJ. Lee SHR, et al. Nat Med. 2023 Jan;29(1):170-179. doi: 10.1038/s41591-022-02112-7. Epub 2023 Jan 5. Nat Med. 2023. PMID: 36604538 Free PMC article.
Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical features, leukemia genomics and minimal residual disease (MRD); however, the pharmacological basis of these prognostic variables …
Contemporary chemotherapy for childhood acute lymphoblastic leukemia (ALL) is risk-adapted based on clinical fea …
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S, Anwar MY, Khalid F, Khan SI, Ali MA, Khattak ZE. Aamir S, et al. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e334-e347. doi: 10.1016/j.clml.2020.12.010. Epub 2020 Dec 17. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33573914
Acute lymphoblastic leukemia (ALL) typically responds better when treated with multiagent chemotherapy in the pediatric and young adolescent populations. ...In 2017, the US Food and Drug Administration approved CD19-specific CAR-T (tisagenlecleucel) therapy f …
Acute lymphoblastic leukemia (ALL) typically responds better when treated with multiagent chemotherapy in the pediatric …
Overview on Aneuploidy in Childhood B-Cell Acute Lymphoblastic Leukemia.
Panuciak K, Nowicka E, Mastalerczyk A, Zawitkowska J, Niedźwiecki M, Lejman M. Panuciak K, et al. Int J Mol Sci. 2023 May 15;24(10):8764. doi: 10.3390/ijms24108764. Int J Mol Sci. 2023. PMID: 37240110 Free PMC article. Review.
Recent years have brought significant progress in the treatment of B-cell acute lymphoblastic leukemia (ALL). This was influenced by both the improved schemes of conventionally used therapy, as well as the development of new forms of treatment. …
Recent years have brought significant progress in the treatment of B-cell acute lymphoblastic leukemia (A …
Molecular processes involved in B cell acute lymphoblastic leukaemia.
Malouf C, Ottersbach K. Malouf C, et al. Cell Mol Life Sci. 2018 Feb;75(3):417-446. doi: 10.1007/s00018-017-2620-z. Epub 2017 Aug 17. Cell Mol Life Sci. 2018. PMID: 28819864 Free PMC article. Review.
This first genetic insult is the major determinant for the prognosis and therapeutic outcome of patients. B cell leukaemia in adults displays similar molecular features as its paediatric counterpart. However, since this disease is highly represented in the in …
This first genetic insult is the major determinant for the prognosis and therapeutic outcome of patients. B cell leukae …
New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.
Moorman AV. Moorman AV. Haematologica. 2016 Apr;101(4):407-16. doi: 10.3324/haematol.2015.141101. Haematologica. 2016. PMID: 27033238 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level. Chromosomal abnormalities are used as diagnostic, prognostic and predictive biomarkers to provide subtype, outcome and drug response information. t(12;21)/ETV6-R …
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level. Chromosomal abnormalities are used …
2,280 results